Sergliflozin etabonate

Sergliflozin etabonate
Clinical data

Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name 2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number	408504-26-7^Y
PubChem CID	9824918
IUPHAR/BPS	4587
ChemSpider	21234810^N
ChEMBL	CHEMBL450044^N
Chemical and physical data
Formula	C₂₃H₂₈O₉
Molar mass	448.463 g/mol
3D model (JSmol)	Interactive image
SMILES CCOC(=O)OCC1C(C(C(C(O1)Oc2ccccc2Cc3ccc(cc3)OC)O)O)O
InChI InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3^N Key:QLXKHBNJTPICNF-UHFFFAOYSA-N^N
^NY (what is this?)

Sergliflozin etabonate (INN/USAN, codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

...
Wikipedia